Post-radiation sarcoma: A study by the Eastern Asian Musculoskeletal Oncology Group

• DOI: 10.1371/journal.pone.0204927
• Publication Date: 2018-10-17T19:20:22Z
• Authors: Min Wook Joo; Yong Koo Kang; Koichi Ogura; Shintaro Iwata; June Hyuk Kim; Won Ju Jeong; Xiaohui Niu; Pramod S. Chinder; Han Soo Kim; Sung Wook Seo; Yang-Guk Chung
• Keywords: Latency stage

The oncologic risk of ionizing radiation is widely known. Sarcomas developing after radiotherapy have been reported, and they are a growing problem because rapid advancements in cancer management screening increased the number long-term survivors. Although many patients undergone treatment Asian countries, scarce reports on post-radiation sarcomas (PRSs) published. We investigated feature prognostic factors PRSs an population. Eastern Musculoskeletal Oncology Group participated this project. Cases obtained from 10 centers were retrospectively reviewed. Patients with genetic malignancy predisposition syndrome, or who had more than one type before development secondary sarcoma excluded. Forty-two high-grade among total 43 analyzed. There 29 females 13 males, median age 58.5 years; 23 bone tumors 19 soft tissue tumors. most common primary lesion was breast cancer. latency period 192 months. no differences dose, time, survival rates between PRSs. site diagnosis pelvic area osteosarcoma malignant fibrous histiocytoma for follow-up 25.5 Five-year metastasis-free overall 14.5% 16.6%, 39.1% 49.6% Survival depending initial metastasis surgery significant sarcomas. study failed to find ethnic differences, it largest review PRS As early recognition through surveillance key optimal management, clinicians should take efforts understand real status PRS.